United Therapeutics Corporation $UTHR Shares Newly Purchased by Vilga Financial Planning LLC

Key Points

• Vilga Financial Planning LLC acquired 20,003 United Therapeutics shares worth approximately $10.8 million, making UTHR its second-largest holding at 6.5% of the portfolio. Institutional investors collectively own 94.08% of the company.
• United Therapeutics reported quarterly EPS of $7.27, exceeding consensus estimates of $6.86, while revenue fell 1.9% year over year to $783.3 million. The stock recently opened at $532.78 and has traded between $409.07 and $609.35 over the past year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $627.31, although insiders sold roughly $187.9 million in shares over the past three months.

Vilga Financial Planning LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 20,003 shares of the biotechnology company's stock, valued at approximately $10,839,000. United Therapeutics makes up 6.5% of Vilga Financial Planning LLC's holdings, making the stock its 2nd largest position.

A number of other institutional investors have also made changes to their positions in the business. Apella Capital LLC raised its stake in shares of United Therapeutics by 27.0% in the third quarter. Apella Capital LLC now owns 451 shares of the biotechnology company's stock worth $246,000 after acquiring an additional 96 shares during the last quarter. Toth Financial Advisory Corp raised its position in shares of United Therapeutics by 100.0% in the 3rd quarter. Toth Financial Advisory Corp now owns 100 shares of the biotechnology company's stock valued at $54,000 after acquiring an additional 50 shares during the period. Whalen Wealth Management Inc. raised its holdings in United Therapeutics by 18.4% in the third quarter. Whalen Wealth Management Inc. now owns 1,118 shares of the biotechnology company's stock worth $606,000 after purchasing an additional 174 shares during the period. QRG Capital Management Inc. raised its stake in United Therapeutics by 3.5% during the 2nd quarter. QRG Capital Management Inc. now owns 3,476 shares of the biotechnology company's stock worth $1,883,000 after buying an additional 116 shares during the period. Finally, Envestnet Portfolio Solutions Inc. raised its position in shares of United Therapeutics by 1.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,445 shares of the biotechnology company's stock worth $1,867,000 after purchasing an additional 60 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Down 2.2%

UTHR stock opened at $532.78 on Friday. United Therapeutics Corporation has a 12 month low of $409.07 and a 12 month high of $609.35. The stock has a market capitalization of $22.85 billion, a P/E ratio of 19.06, a price-to-earnings-growth ratio of 2.73 and a beta of 0.49. The firm has a 50-day moving average price of $511.37 and a 200-day moving average price of $539.93.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics's revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $6.41 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 8,300 shares of the company's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $564.95, for a total value of $4,689,085.00. Following the sale, the executive vice president directly owned 45,172 shares of the company's stock, valued at approximately $25,519,921.40. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $548.95, for a total transaction of $5,215,025.00. Following the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $178,102,984.85. This trade represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 364,728 shares of company stock worth $187,920,726 over the last three months. Insiders own 8.60% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on UTHR. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a report on Thursday, October 1st. Weiss Ratings downgraded shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, August 27th. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Finally, Royal Bank Of Canada increased their price objective on United Therapeutics from $677.00 to $708.00 and gave the stock an "outperform" rating in a research report on Thursday. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $627.31.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.